3 Reasons to Choose Brookfield Asset Management Inc. Over Valeant Pharmaceuticals Intl Inc

Brookfield Asset Management Inc. (TSX: BAM.A)(NYSE:BAM) and Valeant Pharmaceuticals Intl Inc (TSX: VRX)(NYSE:VRX) have a lot of things in common, but Brookfield is the better bet.

The Motley Fool

Brookfield Asset Management (TSX: BAM.A)(NYSE: BAM) and Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX) are two of Canada’s most successful companies. And in recent times, their stock prices have reflected as much. In the past five years, Brookfield shares have increased by 140%, and Valeant’s shares have fared even better, up a whopping 772%.

That being said, both companies have their detractors, and it is easy to see why. They are both very complex, lack transparency, and arguably have employed aggressive accounting.

Yet there are some important differences between the companies too. Below we highlight three of them, and show you why Brookfield is the better option.

1. Real earnings

Make no mistake: both companies have earnings quality issues.

Brookfield owns various assets all over the world, including commercial real estate, renewable energy assets, and other infrastructure projects. How much are these assets worth? Put simply, they’re worth what Brookfield says they’re worth. The company does use external valuations, but mostly for guidance only; the company’s internal valuations reign supreme.

But Valeant’s earnings quality is even worse. The company reports various measures – such as adjusted operating earnings and cash earnings – that exclude some important costs, such as those related to acquisitions.

But here’s the difference: Brookfield gets paid to manage outsiders’ money, resulting in $300 million in fee-related earnings just last year. Overall, the company made over $3 in earnings per share. Meanwhile, Valeant lost nearly $3 per share in 2013.

2. Easier to understand

Again, both companies are very opaque, and wrapping your head around them is not easy.

But Brookfield has made some strides. And better yet, many of its assets are held in publicly-traded entities. So that results in a lot more transparency. The company also does a good job breaking out how much outsider money it earns fees from ($79 billion as of the end of last year), as well as how much fees this results in.

Valeant is a different story. To put this into proper context, the company’s lifeblood is acquisitions. That is how the company grows, and that is how it (supposedly) creates value for shareholders. But acquisitions by nature are very complex, and come with various costs. So when looking at the company as a whole, deciding just what the company is worth is practically impossible.

3. A longer track record

This may be the most important difference between the two companies. On one hand, Brookfield has been managing money wisely for decades. In fact, the company’s share price had returned 19% per year from 1994 to 2013. Over a time period that long, you can’t chalk it up to luck.

On the other hand, Valeant is the product of a merger between two struggling pharmaceutical companies, Biovail and Valeant. And the company’s more recent success can be attributed to new CEO Michael Pearson’s acquisition-first strategy.

But many are convinced that this success will be short-lived. And without a track record as long as Brookfield’s, Valeant has not proven these people wrong. Your best bet is to not take the chance.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »